Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional

On 8 December 2010, Johnson & Johnson and Crucell announced that Johnson & Johnson was making a recommended cash offer for all of the issued and outstanding ordinary shares of Crucell at an offer price of €24.75 per share.

On 22 February 2011, Johnson & Johnson and Crucell announced that Johnson & Johnson has completed the tender offer for Crucell and has declared the offer unconditional. As a result, Crucell will now operate as the center for vaccines within the Johnson & Johnson pharmaceuticals group.

 

 

This section provides all relevant information on this subject:

 

Offer Documentation:

 

• Link to Offer Document (8 December 2010)

 

• Link to Crucell Shareholders' Circular (8 December 2010)

 

Shareholder meetings:

 

• Offer EGM 2011 (8 February 2011) - Link to (audio) webcast and documentation

 

• Informational EGM 2010 (10 December 2010) - Link to (audio) webcast and documentation  

 

Press Releases:

 

• Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs (PDF)

 

• Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional - 22 February 2011 (PDF)

 

• Cucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on US Regulatory Matters - 8 February 2011 (PDF)

  

• Johnson & Johnson Receives Approval from European Commission - 28 January 2011 (PDF)

 

• Johnson & Johnson Launches Recommended Public Offer to Acquire Crucell - 8 December 2010 (PDF)

 

• Johnson & Johnson and Crucell Progress Update: Expect to Commence Public Offer Prior to 10 December 2010 - 30 November 2010 (PDF)

 

• Johnson & Johnson and Crucell Provide Progress Update on Preparations for Public Offer - 29 October 2010 (PDF)

  

• Johnson & Johnson and Crucell Reach Agreement on Intended Public Offer of €24.75 per Ordinary Share of Crucell - 6 October 2010 (PDF)

 

• Johnson & Johnson and Crucell in advanced negotiations for an all cash public offer of €24.75 per ordinary share of Crucell - 17 September 2010 (PDF)

  

About Johnson & Johnson

Caring for the world, one person at a time….inspires and unites the people of Johnson & Johnson.  We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 114,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day throughout the world. For more information www.jnj.com.